GeneScan makes investment in MWG Biotech
This article was originally published in Clinica
Executive Summary
GeneScan Europe, a developer of bioanalytical testing technology based in Freiburg, Germany, has acquired a 25.1% stake in fellow German firm MWG Biotech, the troubled genomics technology provider, writes Stefan Fritsch*. GeneScan has purchased shares from two major shareholders, and E2m ($2.5m) worth of convertible bonds. Furthermore, GeneScan's Dutch parent, Eurofins Ventures, has bought an additional 2 million bonds directly from MWG.